Is a tumor ever too small to send off a genomic assay like Oncotype or Mammoprint in HR positive, HER2 negative stage 1 breast cancer?
There is a gray area in clinical decision making where the practice seems to be different for borderline size tumors such as a 7 mm T1b lesion with no other high risk features. Clinical practice seems to have wide variations based on institutional practices.
Answer from: Medical Oncologist at Academic Institution
The Oncotype DX has been used to identify high risk stage T1b tumors that may benefit from the addition of chemotherapy such as Taxotere/Cytoxan for 4 cycles and has been part of NCCN guidelines for quite some time. We do consider chemotherapy for high risk T1b luminal B tumors (either on basis of h...
Sign in or Register to read more